Table 1 Antibiotics used in this study
From: ESKAPE pathogens rapidly develop resistance against antibiotics in development in vitro
Antibiotic | Abbreviation | Antibiotic class | Generation | Date of approval/clinical phase |
|---|---|---|---|---|
Omadacycline | OMA | Tetracyclines | Recent | 2018 |
Eravacycline | ERA | Recent | 2018 | |
Doxycycline | DOX | Control | 1967 | |
Ceftobiprole | CTO | Cephalosporins | Recent | 2019 |
Cefiderocol | CID | Recent | 2019 | |
Cefepime | CEP | Control | 1994 | |
Delafloxacina | DEL | Topoisomerase inhibitors | Recent | 2017 |
Gepotidacina | GEP | Recent | Phase 3 | |
Zoliflodacin | ZOL | Recent | Phase 3 | |
Moxifloxacina | MOX | Control | 1999 | |
Apramycin | APR | Aminoglycosides | Recent | Phase 1 |
Gentamicin | GEN | Control | 1964 | |
Sulopenem | SUO | Carbapenems | Recent | Phase 3 |
Meropenem | MER | Control | 1996 | |
Tridecaptin M152-P3a | TRD | Membrane-targeting | Recent | Preclinical |
POL-7306a | POL | Recent | Preclinical | |
SCH-79797a | SCH | Recent | Preclinical | |
SPR-206 | SPR | Recent | Phase 1 | |
Polymyxin B | PMB | Control | 1964 |
